SEPARATION AND CONSULTING AGREEMENTSeparation and Consulting Agreement • February 9th, 2022 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
This Separation and Consulting Agreement (“Agreement”), dated as of February 7, 2022, is entered into between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”), and Jerry Lanchbury (“Employee” and, together with the Company, the “Parties” and each a “Party”).
